This has been reported in dailymail.co.uk dated 21 March 2015.
As explained by Professor Stephen Devereux, consultant haematologist at King’s College Hospital in London, chemotherapy kills cancer cells and also normal cells and therefore has a number of side effects.
However, since the Ibrutinib drug is targeted at the B-cells, the side effects are minor. Moreover, it is not necessary for patients to shift to the hospital to get it administered.
On a rough estimate, nearly one in every 25 people will be diagnosed with blood cancer during their lifetime – that would translate into 25,000 people annually in the UK. Out of these, the breakdown would be 2,800 with CLL, the most common type of leukemia, while around 500 will have MCL, a rare type of B-cell lymphoma.
As things now stand, a course of ibrutinib is a costly affair – it would cost up to £74,000 a year – and will be prescribed only to those patients whose disease does not respond to chemotherapy, or those who have relapsed following chemotherapy.
A few more must reads -
Nashik Kumbhmela 2015 – a once in 12-years pilgrimage
Trip to Nashik should take in Shirdi and the Ajanta and Ellora caves
Nashik, a tourist center with links to the epic Ramayana
Nashik, a tourist center with links to the Mahabharata
Kumbhmela 2015 in Nashik – guided tours to wineries and vineyards
Nashik transforms from a place of pilgrimage to an industrial hub
First Russian woman cosmonaut returns to Earth after six-month stay in ISS
European court terms obesity as a disability
Health tips – lose weight without dieting
Sunshine means Vitamin D – good for health in measured dose
No comments:
Post a Comment